Featured Research

from universities, journals, and other organizations

Study uncovers enzyme's double life, critical role in cancer blood supply

Date:
March 4, 2013
Source:
University of Vermont
Summary:
Studied for decades for their essential role in making proteins within cells, several amino acids known as tRNA synthetases were recently found to have an unexpected -- and critical -- additional role in cancer metastasis. Researchers determined that threonyl tRNA synthetase leads a "double life," regulating a pathway used by invasive cancers to induce the formation of new blood vessels, and a new food supply to sustain their growth.

(From left) Adam Mirando, Ph.D., postdoctoral fellow in biochemistry; Tamara Williams, Ph.D., lecturer in nursing and a postdoctoral fellow in pharmacology; Christopher Francklyn, Ph.D., professor of biochemistry; and Karen Lounsbury, Ph.D., professor of pharmacology.
Credit: Photo by Ed Neuert

Studied for decades for their essential role in making proteins within cells, several amino acids known as tRNA synthetases were recently found to have an unexpected -- and critical -- additional role in cancer metastasis in a study conducted collaboratively in the labs of Karen Lounsbury, Ph.D., University of Vermont professor of pharmacology, and Christopher Francklyn, Ph.D., UVM professor of biochemistry. The group determined that threonyl tRNA synthetase (TARS) leads a "double life," functioning as a critical factor regulating a pathway used by invasive cancers to induce angiogenesis -- the formation of new blood vessels -- and a new food supply to sustain their growth.

Related Articles


The teams' research was published online February 21, 2013 in Nature Scientific Reports.

According to Tamara Williams, Ph.D., first author on the study, a lecturer in nursing and postdoctoral fellow in pharmacology at UVM, cancerous tumors quickly outgrow their local blood supply. When they do, the cancer cells send out signals, TARS is secreted, and the angiogenesis process is initiated.

"In our study, we showed that TARS, once thought to only function in the housekeeping role of protein synthesis within cells, 'moonlights' as a secreted signaling agent in the endothelial cells that line vessels, in response to factors commonly produced by cancer cells," says Williams.

The study's in vivo model of angiogenesis was performed using a chick chorioallantoic membrane assay. This experiment utilizes the vascular membrane that surrounds a ten-day-old chicken embryo, which is removed from its shell. Williams and her research teammates placed small pieces of surgical sponges on the surface of the membrane and added compounds, including TARS, to the sponges. The researchers took images of the sponges and surrounding tissues every 24 hours for three days and then analyzed the images to assess the impact of the compounds on local blood vessel development around the sponge. Their test determined whether the compound was angiogenic (creates new blood vessels), had no effect, or was angiostatic (inhibits blood vessel development). Using this assay, the group was able to demonstrate that TARS prompts angiogenesis by increasing the directional movement, or migration, of vessel cells towards the cancer cell signals. The group's research also showed that a potent inhibitor of TARS activity -- called inhibitor BC194 -- blocked its induction of angiogenesis.

"The implications of these novel and surprising findings are substantial for the cancer research community and include potential opportunities to develop new, early, and sensitive diagnostics," Williams says.

"Commercially, compounds that reduce TARS could be used to stop angiogenesis in cancer, compounds that increase TARS could promote angiogenesis, and a laboratory blood test for TARS could serve as a diagnostic for progression in certain cancers," says Kerry Swift, M.S., technology licensing officer in the UVM Office of Technology Commercialization.

Williams adds that the anti-angiogenic activity of the potent inhibitor of TARS paves the way for new therapeutics to block tumor growth and metastasis by stopping TARS-induced angiogenesis.

"These types of therapeutics could be used in combination with other treatments that target and kill cancer cells as part of a personalized cancer medicine approach to treat patients with greater success," she says.

On April 22, 2013, Francklyn will present a poster session on this research, titled "Mode of Action of Bioactive Natural Products," at the annual American Society for Biochemistry and Molecular Biology meeting in Boston, Mass. Lounsbury will present the project at the American Association for Cancer Research meeting, which takes place April 6 to 10, 2013 in Washington, D.C.


Story Source:

The above story is based on materials provided by University of Vermont. The original article was written by Jennifer Nachbur. Note: Materials may be edited for content and length.


Journal Reference:

  1. Tamara F. Williams, Adam C. Mirando, Barrie Wilkinson, Christopher S. Francklyn, Karen M. Lounsbury. Secreted Threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis. Scientific Reports, 2013; 3 DOI: 10.1038/srep01317

Cite This Page:

University of Vermont. "Study uncovers enzyme's double life, critical role in cancer blood supply." ScienceDaily. ScienceDaily, 4 March 2013. <www.sciencedaily.com/releases/2013/03/130304211534.htm>.
University of Vermont. (2013, March 4). Study uncovers enzyme's double life, critical role in cancer blood supply. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2013/03/130304211534.htm
University of Vermont. "Study uncovers enzyme's double life, critical role in cancer blood supply." ScienceDaily. www.sciencedaily.com/releases/2013/03/130304211534.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Reuters - Innovations Video Online (Oct. 29, 2014) A Swedish amputee who became the first person to ever receive a brain controlled prosthetic arm is able to manipulate and handle delicate objects with an unprecedented level of dexterity. The device is connected directly to his bone, nerves and muscles, giving him the ability to control it with his thoughts. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Google To Use Nanoparticles, Wearables To Detect Disease

Google To Use Nanoparticles, Wearables To Detect Disease

Newsy (Oct. 29, 2014) Google X wants to improve modern medicine with nanoparticles and a wearable device. It's all an attempt to tackle disease detection and prevention. Video provided by Newsy
Powered by NewsLook.com
Can Drinking Milk Lead To Early Death?

Can Drinking Milk Lead To Early Death?

Newsy (Oct. 29, 2014) Researchers in Sweden released a study showing heavy milk drinkers face an increased mortality risk from a variety of causes. Video provided by Newsy
Powered by NewsLook.com
Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins